News & Videos - GUERBET - English - Page 2

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA PR Newswire VILLEPINTE, France, March 29, 2022 Priority Review granted by US-FDA March 28, 2022 VILLEPINTE, France , March 29, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted...

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA Priority Review granted by US-FDA March 28, 2022 Villepinte (France), March 29 2022 – Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug...

2021 annual results Revenue at the top of the guidance > +2.8% at current exchange rates (€732.1m) > +7.9% at constant exchange rates and like for like basis (on like-for-like basis 1 ) Satisfactory financial performance > EBITDA margin 2 above expectations: 14.4% at €105.1m versus 14.1% in 2020 > Net income up significantly to €32.6m (compared with €18.2m in 2020) > Sharp decrease in net debt to €217.8m thanks to 2021 free cash flow of €38.8m > Proposed dividend of €0.85 per share...

Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization PR Newswire VILLEPINTE, France, March 7, 2022 VILLEPINTE, France , March 7, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging, announces it will more than double its line of microcatheters and launch a new line of guidewires, resulting in a broad range of interventional imaging and embolization solutions available. The company obtained its original offering...

Guerbet Announces Appointment of Jared Houk as Commercial Vice President for North America PR Newswire PRINCETON, N.J., Jan. 12, 2022 PRINCETON, N.J. , Jan. 12, 2022 /PRNewswire/ -- Guerbet LLC, the US affiliate of Guerbet, announced today that Jared Houk has been appointed Commercial Vice President, North America . In this role, Houk will oversee and ensure the growth of Guerbet diagnostic and interventional solutions together with the digital and AI portfolio. Guerbet Announces Appointment of...

2021 Corporate Social Responsibility Gaïa-Index: Guerbet consolidates its position as leader in the “Healthcare” category Villepinte (France), January 4, 2022 (18:00 CET) - Gaïa-Index, a subsidiary of EthiFinance and leader in the ESG (environmental, social and governance) rating of listed French mid-caps, has ranked Guerbet the best company in the healthcare category for the third year running. This year, Guerbet also sits in 10 th place in the national rankings. In terms of its overall...

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol PR Newswire MILAN, Italy, Dec. 14, 2021 Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under separate brands Gadopiclenol is a next-generation, macrocyclic contrast agent with high-relaxivity, intended to improve lesion detection and visualization in MRI, with lower doses of gadolinium compared to other...

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under separate brands Gadopiclenol is a next-generation, macrocyclic contrast agent with high-relaxivity, intended to improve lesion detection and visualization in MRI, with lower doses of gadolinium compared to other agents on the market Guerbet and Bracco...

2021 half-year results Strong sales pickup across all activities > H1 sales: €363.1 million (+9.6% 1 ) with a sharp increase in Q2 Solid financial structure > H1 EBITDA margin 2 : 17.1% at €62.3 million (versus 14.7% in H1 2020 at €53.3 million) > Strong net income growth at €23.4 million (6.4% of revenue) versus €8.2 million (2.3% of revenue) in H1 2020. > Net debt decrease at €249.3 million 2021 objectives: Confirmation of guidance > 2021 EBITDA margin of at least 14.1% of annual...

Marc Massiot appointed to Guerbet’s Board of Directors Villepinte (France), May 31, 2021 (6:00 p.m. CET) – Guerbet (FR0000032526 GBT), a global leader in medical imaging, has announced the election of Marc Massiot as director for a six-year term. This nomination was approved at Guerbet’s Annual General Shareholders’ Meeting on May 28. Marc Massiot , aged 60, is founder and manager of Enaxante, a business advisory and training firm operating in the field of healthcare, as well as Espace...

Q1 2021 revenue Gradual improvement in activity: Reported revenue of €176.3 million, impacted by a significant currency effect -3.0% at constant exchange rates (CER 1 ) and on a like-for-like basis 2 Villepinte, April 22, 2021 – Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is reporting its revenue for the first quarter of 2021. As of March 31, 2021, reported revenue was €176.3 million, down 11.5% from March 31, 2020, including an...

Additional information related to 2021 financial outlook Villepinte, March 29, 2021 – Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is detailing information related to 2021 outlook disclosed in the March 24 th , 2021 press release entitled “2020 Annual Results”. In terms of profitability, the company is targeting the following EBITDA trends: Short term, a growing EBITDA in 2021, with a minimum rate EBITDA/SALES equal to 2020 (14.1%)...

2020 annual results Revenue in line with forecasts despite the health crisis: -12.8% at current exchange rates at €712.3 million -10.0% at constant exchange rates (CER) (1) Resilient EBITDA (2) margin at 14.1% Proposed dividend maintained at €0.70/share Higher free cash flow at €40 million with significant working capital improvement Reduction of net debt to €257 million Confirmation of the strategic roadmap in 2021: Strong growth in Interventional Imaging and delivery systems...

Gadopiclenol: positive results for Phase III clinical trials Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI). Its diagnostic efficacy and safety have been evaluated in two Phase III clinical studies with a dose of gadolinium reduced by half compared to products already available on the market. Guerbet is planning to make regulatory submissions from early 2022 in a wide range of indications in adults and children from 2 years of age....

INFORMATION ABOUT GUERBET'S COMBINED GENERAL MEETING DATE AND CONDITIONS OF BROADCASTING Guerbet's Combined General Meeting will be held on Friday, May 29, 2020, at 3:00 p.m. (in closed proceedings). In view of the coronavirus (COVID-19) pandemic, travel restrictions, and the lockdown measures imposed by the government, and in accordance with the provisions of Article 4 of Ordinance No. 2020-321 of March 25, 2020, adapting the rules applicable to meetings and deliberation of corporate bodies of...

1 st quarter 2020 revenue Revenue growth over 1 st quarter 2020 +1.0% at current exchange rates at €199.2m +1.4% at constant exchange rates at €199.9 million Activity affected by the COVID-19 crisis in the 2 nd quarter Villepinte, April 23, 2020 – Guerbet (FR0000032526), a global leader in medical imaging, is reporting its revenue for the first quarter of its 2020 financial year. Revenue totaled €199.2 million at March 31, up 1.0%, including a favorable forex impact of €0.7 million. At...

2019 revenue Activity growth consistent with the objectives: +3.5% at current exchange rates and +2.0% at constant exchange rates Villepinte, 13 February 2020 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting 2019 revenue of €816.9 million, up 3.5% from 2018, including a favourable forex impact of €11.3 million. Revenue was up 2.0% at €805.6 million at constant exchange rates 1 . Fourth quarter 2019 revenue was €211.2...

Guerbet Announces Appointment of Thomas McLaughlin as Vice President for North America PR Newswire PRINCETON, N.J., Jan. 8, 2020 PRINCETON, N.J. , Jan. 8, 2020 /PRNewswire/ -- Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that Thomas McLaughlin has been appointed Vice President, North America . In this role, McLaughlin will oversee and ensure the growth of Guerbet diagnostic and interventional solutions together with the digital and AI...

David Hale appointed CEO of Guerbet as from January 1, 2020 to accelerate deployment of the Group’s strategy Villepinte (France), December 18 th , 2019 (6 :00 pm CEST) – Guerbet’s Board of Directors announces the appointment of David Hale as Chief Executive Officer as from January 1, 2020. Chief Commercial Officer and Group Executive Committee member since February 2018, David Hale takes over the position from Yves L’Epine, who has been CEO since end of 2011. For 2019, Guerbet confirms...

Vectorio® Registration in India, An Innovative Medical Device for cTACE Procedures Villepinte (France) – December 3 th , 2019 - 06:00pm - Guerbet (GBT) announces that the Ministry of Health & Family Welfare delivered registration for its innovative conventional Trans-Arterial Chemo-Embolization (cTACE) mixing and injection system, Vectorio ® , in India. Vectorio ® is a set of Lipiodol ® resistant medical devices (1) including syringes, patented stopcock and sampling devices. Vectorio ® is...